REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***.
English translation of the executed copy
Sole Agency Agreement for Baolijin
Party A: Chengdu Institute of Biological Products
Party B: Liaoning Sunshine Pharmaceutical Co., Ltd.
Chengdu Institute of Biological Products (hereinafter referred to as “Party A”) and Liaoning Sunshine Pharmaceutical Co., Ltd.
(hereinafter referred to as “Party B”) have entered into this Agreement on the basis of the principles of mutual benefits and joint
development pursuant to the relevant Chinese laws and regulations and upon friendly negotiations between the two parties, for
the purpose of making full use of their respective advantages and further expanding the market.
1. Party A has appointed Party B as the nationwide exclusive and sole agent for its product “Recombinant Human Granulocyte
Colony Stimulating Factor” injection (product name “Baolijin”) to be fully responsible for the sale and promotion of the product
in the China market. During the term of this agency agreement, Party A may not sell the product directly or indirectly to a third
party, or delegate any third party to sell the product.
2. The product “Recombinant Human Granulocyte Colony-Stimulating Factor” shall include but not limited to the specifications
and the types of injection set out in the table below (the amount below is in Renminbi. The prices are exclusive of tax. Unit:
3. Term of agency: From August 1, 2006 to December 31, 2011, which period shall be divided into five agency years. The first
agency year shall commence from August 1, 2006 to December 31, 2007, while the remaining four agency years shall be divided
by calendar year. Upon expiry of the term of agency, Party B may have the priority to renew this agreement under the same
terms. A renewed agreement shall be entered into one quarter before the expiry of the term of agency. If both parties fail to agree
upon the renewal of the Agreement, they shall enter into a supplemental agreement in c